ON 013105

Phase 3Small molecule

TTraws Pharma, Inc.

ON 013105 is one of 131 small molecule programs targeting Lymphoid Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

130

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoid LeukemiaActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Pancreatic CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Lymphoid LeukemiaPhase 1

Active, not recruiting

Myelodysplastic SyndromePhase 1/Phase 2

Active, not recruiting

Pancreatic CancerPhase 3

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

ON 013105

TTraws Pharma, Inc.

Phase 3

1 2

Gemzar

GGynecologic Oncology Group

Byetta

1 4

Medrol

Pfizer

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

ABI-007

Bristol-Myers Squibb

Preclinical

2 7

LDE225

Novartis

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Thiazolidinediones

Sanofi

Preclinical

1 10

Active Comparator

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome5 trials

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Withdrawn·TTraws Pharma, Inc.·Phase 1/2·NCT00867061

Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk

Completed·TTraws Pharma, Inc.·Phase 2·NCT00906334·14 enrolled

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts

Completed·TTraws Pharma, Inc.·Phase 3·NCT01241500·299 enrolled

Show 2 more trials

Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome

Completed·TTraws Pharma, Inc.·Phase 1·NCT01048619·36 enrolled

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

Completed·TTraws Pharma, Inc.·Phase 1·NCT00854646·22 enrolled

Advanced Solid Tumors1 trial

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

Completed·TTraws Pharma, Inc.·Phase 1·NCT01165905·10 enrolled

Infusion1 trial

Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML

Completed·TTraws Pharma, Inc.·Phase 1/2·NCT00854945·36 enrolled

Pancreatic Cancer1 trial

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Completed·TTraws Pharma, Inc.·Phase 3·NCT01360853·160 enrolled

Solid Tumors1 trial

Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors

Completed·TTraws Pharma, Inc.·Phase 1·NCT01125891·39 enrolled

3 more indications

Ovarian Cancer1 trial

Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients

Completed·TTraws Pharma, Inc.·Phase 2·NCT00856791·1 enrolled

Oxaliplatin1 trial

Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin

Completed·TTraws Pharma, Inc.·Phase 1·NCT00861328·18 enrolled

Lymphoid Leukemia1 trial

Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia

Terminated·TTraws Pharma, Inc.·Phase 1·NCT01049113·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for ON 013105. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ON 013105 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ON 013105. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Traws Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTraws Pharma, Inc.

ON 013105

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myelodysplastic Syndrome5 trials

Advanced Solid Tumors1 trial

Infusion1 trial

Pancreatic Cancer1 trial

Solid Tumors1 trial

Ovarian Cancer1 trial

Oxaliplatin1 trial

Lymphoid Leukemia1 trial

References

Drug Info

Quick Facts

Related News